ACTRN12615000121561终止3 期
A randomised, double-blind, multi-site, parallel arm, fixed dose, placebo-controlled trial of the effects of morphine on exercise capacity and other outcomes of pulmonary rehabilitation in chronic obstructive pulmonary disease (COPD)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit(—)
- 性别
- All
入选标准
- •* Eligible for pulmonary rehabilitation as judged by the treating physician and the investigator
- •* COPD verified by a post-bronchodilator FEV1/FVC<0.7 on a previous spirometry
- •* Age 18 years or more
- •* English speaking and able to read study questionnaires (5th grade level)
- •* On stable medications for breathlessness over the prior week except routine as needed” medications
- •* Participant is capable of giving informed written consent, completing assessments, and complying with the study procedures
- •* Breathlessness of a level 3 or 4 on the mMRC dyspnoea scale
排除标准
- •* Unstable cardiac or vascular disease within the previous four weeks.
- •* Severely restricted performance status with AKPS score < 50 at baseline.
- •* Anaemia with hemoglobin <10.0g/dL as measured within one month of baseline evaluation for which transfusion would be indicated in the view of the treating physician.
- •* History of chronic alcoholism or drug misuse problem.
- •* On regular or ‘as needed’ (PRN) opioid medications, including codeine preparations at or above a dose equivalent to 20mg of morphine sulphate per 24 hours.
- •* Renal dysfunction with creatinine clearance calculated <20 mls/minute using the MDRD formula. (Severe renal impairment – AMH)
- •* Hepatic impairment with serum alkaline phosphatase, total bilirubin, ALT or AST > four times the upper limit of normal for the local laboratory.
- •* Documented central hypoventilation syndrome.
- •* Evidence of respiratory depression with resting respiratory rate < 8.
- •* Participation in the current study at any time, or in a clinical study of a new chemical entity within the month prior to study entry
- •* History of adverse reactions to morphine or constituents in the placebo.
- •* Pregnant or breastfeeding.
- •* Unable to achieve two baseline 6MWTs of at least 200m each
研究者
相似试验
进行中(未招募)
不适用
Clinical study to investigate the efficacy and safety of an ointment that increases the blood circulation in the skin, containing 2.5% Nicoboxil and 0.4% Nonivamide, in comparison to ointments that contain only one of both compounds, or none of them (placebo) for the treatment of acute low back paiAcute low back painEUCTR2011-003890-27-DEBoehringer Ingelheim Pharma GmbH & Co. KG
进行中(未招募)
1 期
Dose-ranging study of nemolizumab in atopic dermatitisAtopic dermatitisEUCTR2016-005025-37-PLGALDERMA R&D, SNC351
进行中(未招募)
1 期
Dose-ranging study of nemolizumab in atopic dermatitisAtopic dermatitisEUCTR2016-005025-37-FRGALDERMA R&D, SNC250
进行中(未招募)
1 期
Dose-ranging study of nemolizumab in atopic dermatitisAtopic dermatitisEUCTR2016-005025-37-DEGALDERMA R&D, SNC250
已完成
不适用
A multicentre, double-blind, randomised, parallel group, placebo-controlled trial of LAX-101 (ethyl eicosapentaenoate [EPA]) in patients with a new or recurrent episode of depressioDepressionMental and Behavioural DisordersDepressive episodeISRCTN63565713axdale Ltd (UK)
